{
    "title": "Biogen's 2022 forecast well below Street view on Alzheimer's drug uncertainty",
    "url": "https://www.dailymail.co.uk/wires/reuters/article-10472545/Biogen-2022-profit-forecast-misses-estimates-Aduhelm-woes.html",
    "date": "2022-02-03",
    "keywords": [
        "company",
        "coverage",
        "decision",
        "drug",
        "biogen",
        "proposal",
        "forecast",
        "profit",
        "cms",
        "development",
        "business",
        "vounatsos",
        "aduhelm",
        "share",
        "inc",
        "thursday",
        "street",
        "stall",
        "medicaid",
        "medicare",
        "january",
        "part",
        "april",
        "officer",
        "michael",
        "mcdonnell",
        "latestage",
        "neuroscience",
        "analyst",
        "salim",
        "back",
        "wall",
        "base",
        "decline",
        "pipeline",
        "deal",
        "question",
        "access",
        "executive",
        "michel",
        "group",
        "companys",
        "program",
        "form",
        "time",
        "tecfidera",
        "pressure",
        "competition",
        "fullyear",
        "quarter",
        "reporting",
        "bengaluru",
        "editing",
        "chakrabarty",
        "bill",
        "berkrot"
    ],
    "category": [
        "wires",
        "reuters"
    ]
}